<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02885025</url>
  </required_header>
  <id_info>
    <org_study_id>CLNB-03-15F</org_study_id>
    <nct_id>NCT02885025</nct_id>
  </id_info>
  <brief_title>Effects of Broccoli Sprout Extract on Allergy Rhinitis</brief_title>
  <official_title>Effects of Broccoli Sprout Extract on Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allergic rhinitis is a common illness suffered among US Veterans. There are medications that
      help relieve allergy symptoms, including nasal steroid sprays and antihistamines. Some
      patients have increase symptoms with exposure to their trigger, such as a grasses when
      combined with pollution due to oxidative stress from pollution. In this study, patients with
      allergic rhinitis to grass will be given broccoli sprout extract that contains an antioxidant
      sulforaphane do see if there is beneficial effect in these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allergic rhinitis is a common illness suffered among US Veterans. Despite the availability of
      medications, many patients fail to get adequate control of symptoms especially in high
      pollutant areas. Southern California air pollutants, like diesel exhaust particles may act as
      adjuvants to allergens leading to an exaggerated allergic response in certain individuals.
      These individuals may lack adequate Glutathione transferase activity; necessary to protect
      cells against pollutant induced oxidative stress. Sulforaphane has been shown to protect
      against oxidative stress. The investigators hypothesize consumption of foods containing high
      levels of sulforaphane are beneficial to US Veterans with GST deficiencies suffering from
      allergic rhinitis. In the investigators' preliminary data, the investigators discovered
      administration of broccoli sprout extract rich in sulforaphane leads to diminished nasal
      inflammatory reaction brought on by diesel exhaust particles though did not have sufficient
      patient numbers to prove an association with GST deficiency. The investigators propose a 3
      week randomized clinical trial comparing broccoli sprout extract consumption with nasal
      corticosteroid administration after subjects with allergic rhinitis undergo a Timothy,
      Bermuda or Johnson grass nasal challenge. In Aims 1 and 2, the investigators will compare
      clinical (nasal symptom scores and peak nasal inspiratory flows) and laboratory (inflammatory
      cytokines, eosinophil cationic protein, tryptase) measurements between four groups: nasal
      corticosteroid, broccoli sprout extract, nasal corticosteroid plus broccoli sprout extract,
      and placebo. Aim 3 focuses on exploratory genetic analysis of the 3 glutathione S-transferase
      (GST) genes to determine if correlations exist between the inability to produce GST enzyme
      and the response to broccoli sprout extract. At the conclusion of this study, the
      investigators will gain further knowledge of which patients benefit from anti-oxidant
      nutritional supplementation in treating allergic rhinitis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Actual">March 12, 2019</completion_date>
  <primary_completion_date type="Actual">March 12, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Nasal Symptom Score (TNSS) Change From Baseline to 3 Weeks of Randomly Assigned Treatment</measure>
    <time_frame>measures at various points following challenge at baseline and 21 days</time_frame>
    <description>The Immediate Total Nasal Symptom Score (TNSS): The TNSS has been used in prior interventional studies to evaluate different treatment modes for allergic rhinitis. The score will consist of subjects rating 4 symptoms (nasal congestion/postnasal drainage, nasal pruritus, rhinorrhea, or sneezing) on a scale of 0 to 3, where 0=no symptoms present, 1=mild symptoms that do not interfere with activity, 2=moderate symptoms that are slightly bothersome symptoms with slight interference with activity and/or nighttime sleep, or 3=severe symptoms with interference with activity and nighttime sleep. Thus minimal value would be 0 vs. maximal value would be a score of 12. A higher score correlates with higher rhinitis activity. Diminished scores following an intervention is consistent with an improvement in rhinitis symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Nasal Inspiratory Flow (PNIF) Change From Baseline to 3 Weeks of Randomly Assigned Treatment</measure>
    <time_frame>21 days (from randomization to completion)</time_frame>
    <description>peak nasal inspiratory flow (PNIF) measures the peak flow during nasal inspiration with an approved device utilized in other studies. Measurements will be performed with TNSS (above).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interleukin 5 (IL5)</measure>
    <time_frame>21 days (from randomization to completion)</time_frame>
    <description>Interleukin 5 (IL5) is considered a T2 cytokine that increases with exacerbations of atopic disease, including allergic rhinitis. Cytokine measurements are in pg/ml. Values are recorded with log transformation. Note that measurements are on a continuous score. Lower values are consistent with less T2 inflammation which is consistent with diminished or lower atopic/allergic response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 4 (IL4)</measure>
    <time_frame>21 days (from randomization to completion)</time_frame>
    <description>Interleukin 4 (IL4) is considered a T2 cytokine that increases with exacerbations of atopic disease, including allergic rhinitis. Cytokine measurements are in pg/ml. Values are recorded with log transformation. Note that measurements are on a continuous score. Lower values are consistent with less T2 inflammation which is consistent with diminished or lower atopic/allergic response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 6 (IL6)</measure>
    <time_frame>21 days (from randomization to completion)</time_frame>
    <description>Interleukin 6 is a cytokine present during inflammatory process. This is recorded in pg/ml. Below is the log transformation of the pg/ml unit. Note that measurements are on a continuous score. Lower values are consistent with less inflammation which could occur with an inflammatory response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 8 (IL8)</measure>
    <time_frame>21 days (from randomization to completion)</time_frame>
    <description>Interleukin 8 s a cytokine that will increase with inflammation. Below is the log transformation of the pg/ml unit. Note that measurements are on a continuous score. Lower values are consistent with less inflammation which could occur with an inflammatory response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 13 (IL13)</measure>
    <time_frame>21 days (from randomization to completion)</time_frame>
    <description>Interleukin 13 (IL13) is considered a T2 cytokine that increases with exacerbations of atopic disease, including allergic rhinitis. Cytokine measurements are in pg/ml. Values are recorded with log transformation. Note that measurements are on a continuous score. Lower values are consistent with less T2 inflammation which is consistent with diminished or lower atopic/allergic response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 1 Beta (IL1b)</measure>
    <time_frame>21 days (from randomization to completion)</time_frame>
    <description>IL1b is a cytokine that will increase with inflammation. Below is the log transformation of the pg/ml unit. Note that measurements are on a continuous score. Lower values are consistent with less inflammation which could occur with an inflammatory response.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Rhinitis,Allergic</condition>
  <arm_group>
    <arm_group_label>BSE + Nasal Fluticasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects will be randomized into 1 of 4 arms:
Broccoli Sprout Extract + Nasal Fluticasone
Broccoli Sprout Extract + normal saline nasal spray
Placebo Pill + Nasal Fluticasone
Placebo Pill + normal saline nasal spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Broccoli Sprout Extract + normal saline nasal spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects will be randomized into 1 of 4 arms:
Broccoli Sprout Extract + Nasal Fluticasone
Broccoli Sprout Extract + normal saline nasal spray
Placebo Pill + Nasal Fluticasone
Placebo Pill + normal saline nasal spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Pill + Nasal Fluticasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects will be randomized into 1 of 4 arms:
1. Broccoli Sprout Extract + Nasal Fluticasone 2 Broccoli Sprout Extract + normal saline nasal spray 3. Placebo Pill + Nasal Fluticasone 4. Placebo Pill + normal saline nasal spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Pill + normal saline nasal spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subjects will be randomized into 1 of 4 arms:
Broccoli Sprout Extract + Nasal Fluticasone
Broccoli Sprout Extract + normal saline nasal spray
Placebo Pill + Nasal Fluticasone
Placebo Pill + normal saline nasal spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Broccoli Sprout Extract</intervention_name>
    <description>Broccoli Sprout Extract contains the antioxidant Sulforaphane which is the active ingredient being studies.</description>
    <arm_group_label>BSE + Nasal Fluticasone</arm_group_label>
    <arm_group_label>Broccoli Sprout Extract + normal saline nasal spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone nasal</intervention_name>
    <description>fluticasone is a nasal steroid that is currently approved for treatment of allergic rhinitis.</description>
    <arm_group_label>BSE + Nasal Fluticasone</arm_group_label>
    <arm_group_label>Placebo Pill + Nasal Fluticasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>broccoli sprout extract placebo</intervention_name>
    <description>a tablet similar to the actual broccoli sprout extract though without BSE.</description>
    <arm_group_label>Placebo Pill + Nasal Fluticasone</arm_group_label>
    <arm_group_label>Placebo Pill + normal saline nasal spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline nasal spray</intervention_name>
    <description>normal saline to replace nasal fluticasone in specific arms of the study</description>
    <arm_group_label>Broccoli Sprout Extract + normal saline nasal spray</arm_group_label>
    <arm_group_label>Placebo Pill + normal saline nasal spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion Criteria

          1. Females and males 18 years or older.

          2. History consistent with seasonal allergic rhinitis consistent with grass allergy
             (symptoms during summer months, June through August, for at least two consecutive
             seasons).

          3. Not currently taking any medications for allergic rhinitis.

          4. Provide written informed consent.

          5. Willing and able to comply with all aspects of the protocol.

        Exclusion Criteria:

          1. The subject has any uncontrolled or serious disease, or any medical or surgical or
             condition that in the opinion of the investigator(s) could affect the subject's safety
             and/or interfere with the study assessments.

          2. History of anaphylaxis to environmental allergens or an unknown trigger.

          3. History of broccoli allergy

          4. Recent upper respiratory infection (less than 4 weeks prior to study) or other active
             Infection.

          5. Active smoker

          6. Currently receiving allergy immunotherapy.

          7. History of rhinitis exacerbation within the past 2 weeks.

          8. Use of non-selective Beta-Blocker.

          9. Inability to give written informed consent.

         10. History or evidence of non-stable cognitive capacity within less than 1 year (i.e.
             Alzheimer's disease, dementia, bipolar disorder) that in the opinion of the
             investigator(s) could affect the subject's safety and/or interfere with the study
             assessments.

         11. Pregnancy

         12. Perennial rhinitis

         13. Uncontrolled asthma

         14. Forced Expiratory Volume in 1 second &lt;70% predicted at screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhaoping Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Greater Los Angeles Healthcare System, West Los Angeles, CA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Stephen Yusin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Greater Los Angeles Healthcare System, West Los Angeles, CA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Greater Los Angeles Healthcare System, West Los Angeles, CA</name>
      <address>
        <city>West Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 23, 2016</study_first_submitted>
  <study_first_submitted_qc>August 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2016</study_first_posted>
  <results_first_submitted>April 7, 2020</results_first_submitted>
  <results_first_submitted_qc>May 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 19, 2020</results_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypersensitivity</keyword>
  <keyword>antioxidants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT02885025/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT02885025/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from the VA Greater Los Angeles Healthcare System Allergy Immunology Clinic</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>BSE + Nasal Fluticasone</title>
          <description>subjects will be randomized into 1 of 4 arms:
BSE + Nasal Fluticasone
BSE + normal saline nasal spray
Placebo Pill + Nasal Fluticasone
Placebo Pill + normal saline nasal spray
Broccoli Sprout Extract: Broccoli Sprout Extract contains the antioxidant Sulforaphane which is the active ingredient being studies.
fluticasone nasal: fluticasone is a nasal steroid that is currently approved for treatment of allergic rhinitis.</description>
        </group>
        <group group_id="P2">
          <title>BSE + Normal Saline Nasal Spray</title>
          <description>subjects will be randomized into 1 of 4 arms:
BSE + Nasal Fluticasone
BSE + normal saline nasal spray
Placebo Pill + Nasal Fluticasone
Placebo Pill + normal saline nasal spray
Broccoli Sprout Extract: Broccoli Sprout Extract contains the antioxidant Sulforaphane which is the active ingredient being studies.
normal saline nasal spray: normal saline to replace nasal fluticasone in specific arms of the study</description>
        </group>
        <group group_id="P3">
          <title>Placebo Pill + Nasal Fluticasone</title>
          <description>subjects will be randomized into 1 of 4 arms:
BSE + Nasal Fluticasone
BSE + normal saline nasal spray
Placebo Pill + Nasal Fluticasone
Placebo Pill + normal saline nasal spray
fluticasone nasal: fluticasone is a nasal steroid that is currently approved for treatment of allergic rhinitis.
broccoli sprout extract placebo: a tablet similar to the actual broccoli sprout extract though without BSE.</description>
        </group>
        <group group_id="P4">
          <title>Placebo Pill + Normal Saline Nasal Spray</title>
          <description>subjects will be randomized into 1 of 4 arms:
BSE + Nasal Fluticasone
BSE + normal saline nasal spray
Placebo Pill + Nasal Fluticasone
Placebo Pill + normal saline nasal spray
broccoli sprout extract placebo: a tablet similar to the actual broccoli sprout extract though without BSE.
normal saline nasal spray: normal saline to replace nasal fluticasone in specific arms of the study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 47 subjects had a positive reaction to the up dose grass allergen challenge that began with 75 subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>BSE + Nasal Fluticasone</title>
          <description>subjects will be randomized into 1 of 4 arms:
BSE + Nasal Fluticasone
BSE + normal saline nasal spray
Placebo Pill + Nasal Fluticasone
Placebo Pill + normal saline nasal spray
Broccoli Sprout Extract: Broccoli Sprout Extract contains the antioxidant Sulforaphane which is the active ingredient being studies.
fluticasone nasal: fluticasone is a nasal steroid that is currently approved for treatment of allergic rhinitis.</description>
        </group>
        <group group_id="B2">
          <title>BSE + Normal Saline Nasal Spray</title>
          <description>subjects will be randomized into 1 of 4 arms:
BSE + Nasal Fluticasone
BSE + normal saline nasal spray
Placebo Pill + Nasal Fluticasone
Placebo Pill + normal saline nasal spray
Broccoli Sprout Extract: Broccoli Sprout Extract contains the antioxidant Sulforaphane which is the active ingredient being studies.
normal saline nasal spray: normal saline to replace nasal fluticasone in specific arms of the study</description>
        </group>
        <group group_id="B3">
          <title>Placebo Pill + Nasal Fluticasone</title>
          <description>subjects will be randomized into 1 of 4 arms:
BSE + Nasal Fluticasone
BSE + normal saline nasal spray
Placebo Pill + Nasal Fluticasone
Placebo Pill + normal saline nasal spray
fluticasone nasal: fluticasone is a nasal steroid that is currently approved for treatment of allergic rhinitis.
broccoli sprout extract placebo: a tablet similar to the actual broccoli sprout extract though without BSE.</description>
        </group>
        <group group_id="B4">
          <title>Placebo Pill + Normal Saline Nasal Spray</title>
          <description>subjects will be randomized into 1 of 4 arms:
BSE + Nasal Fluticasone
BSE + normal saline nasal spray
Placebo Pill + Nasal Fluticasone
Placebo Pill + normal saline nasal spray
broccoli sprout extract placebo: a tablet similar to the actual broccoli sprout extract though without BSE.
normal saline nasal spray: normal saline to replace nasal fluticasone in specific arms of the study</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PNIF</title>
          <description>Peak Nasal Inspiratory Flow: Range is 0 - 400 L/min. Note that increase in value is consistent with decreased nasal resistance consistent with an improvement.</description>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105" spread="21.2"/>
                    <measurement group_id="B2" value="120" spread="14.1"/>
                    <measurement group_id="B3" value="172.5" spread="31.8"/>
                    <measurement group_id="B4" value="170" spread="28.3"/>
                    <measurement group_id="B5" value="155" spread="49.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Nasal Symptom Score (TNSS) Change From Baseline to 3 Weeks of Randomly Assigned Treatment</title>
        <description>The Immediate Total Nasal Symptom Score (TNSS): The TNSS has been used in prior interventional studies to evaluate different treatment modes for allergic rhinitis. The score will consist of subjects rating 4 symptoms (nasal congestion/postnasal drainage, nasal pruritus, rhinorrhea, or sneezing) on a scale of 0 to 3, where 0=no symptoms present, 1=mild symptoms that do not interfere with activity, 2=moderate symptoms that are slightly bothersome symptoms with slight interference with activity and/or nighttime sleep, or 3=severe symptoms with interference with activity and nighttime sleep. Thus minimal value would be 0 vs. maximal value would be a score of 12. A higher score correlates with higher rhinitis activity. Diminished scores following an intervention is consistent with an improvement in rhinitis symptoms.</description>
        <time_frame>measures at various points following challenge at baseline and 21 days</time_frame>
        <population>intent to treat population (all participants assigned to 1 of the 4 groups above).</population>
        <group_list>
          <group group_id="O1">
            <title>BSE + Nasal Fluticasone</title>
            <description>patients received combination of broccoli sprout extract tablet and nasal fluticasone for a total of 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>BSE + Normal Saline Nasal Spray</title>
            <description>Patients received broccoli sprout extract tablets and nasal saline spray for 3 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Pill + Nasal Fluticasone</title>
            <description>Patients received placebo tablet and nasal fluticasone for 3 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Pill + Normal Saline Nasal Spray</title>
            <description>Patients received placebo tablet and normal saline nasal spray for 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Total Nasal Symptom Score (TNSS) Change From Baseline to 3 Weeks of Randomly Assigned Treatment</title>
          <description>The Immediate Total Nasal Symptom Score (TNSS): The TNSS has been used in prior interventional studies to evaluate different treatment modes for allergic rhinitis. The score will consist of subjects rating 4 symptoms (nasal congestion/postnasal drainage, nasal pruritus, rhinorrhea, or sneezing) on a scale of 0 to 3, where 0=no symptoms present, 1=mild symptoms that do not interfere with activity, 2=moderate symptoms that are slightly bothersome symptoms with slight interference with activity and/or nighttime sleep, or 3=severe symptoms with interference with activity and nighttime sleep. Thus minimal value would be 0 vs. maximal value would be a score of 12. A higher score correlates with higher rhinitis activity. Diminished scores following an intervention is consistent with an improvement in rhinitis symptoms.</description>
          <population>intent to treat population (all participants assigned to 1 of the 4 groups above).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.5277" spread="0.1048"/>
                    <measurement group_id="O2" value="-.5484" spread=".0014"/>
                    <measurement group_id="O3" value="-.8359" spread="0.3903"/>
                    <measurement group_id="O4" value="-.181" spread=".0846"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak Nasal Inspiratory Flow (PNIF) Change From Baseline to 3 Weeks of Randomly Assigned Treatment</title>
        <description>peak nasal inspiratory flow (PNIF) measures the peak flow during nasal inspiration with an approved device utilized in other studies. Measurements will be performed with TNSS (above).</description>
        <time_frame>21 days (from randomization to completion)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BSE + Nasal Fluticasone</title>
            <description>subjects will be randomized into 1 of 4 arms:
BSE + Nasal Fluticasone
BSE + normal saline nasal spray
Placebo Pill + Nasal Fluticasone
Placebo Pill + normal saline nasal spray
Broccoli Sprout Extract: Broccoli Sprout Extract contains the antioxidant Sulforaphane which is the active ingredient being studies.
fluticasone nasal: fluticasone is a nasal steroid that is currently approved for treatment of allergic rhinitis.</description>
          </group>
          <group group_id="O2">
            <title>BSE + Normal Saline Nasal Spray</title>
            <description>subjects will be randomized into 1 of 4 arms:
BSE + Nasal Fluticasone
BSE + normal saline nasal spray
Placebo Pill + Nasal Fluticasone
Placebo Pill + normal saline nasal spray
Broccoli Sprout Extract: Broccoli Sprout Extract contains the antioxidant Sulforaphane which is the active ingredient being studies.
normal saline nasal spray: normal saline to replace nasal fluticasone in specific arms of the study</description>
          </group>
          <group group_id="O3">
            <title>Placebo Pill + Nasal Fluticasone</title>
            <description>subjects will be randomized into 1 of 4 arms:
BSE + Nasal Fluticasone
BSE + normal saline nasal spray
Placebo Pill + Nasal Fluticasone
Placebo Pill + normal saline nasal spray
fluticasone nasal: fluticasone is a nasal steroid that is currently approved for treatment of allergic rhinitis.
broccoli sprout extract placebo: a tablet similar to the actual broccoli sprout extract though without BSE.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Pill + Normal Saline Nasal Spray</title>
            <description>subjects will be randomized into 1 of 4 arms:
BSE + Nasal Fluticasone
BSE + normal saline nasal spray
Placebo Pill + Nasal Fluticasone
Placebo Pill + normal saline nasal spray
broccoli sprout extract placebo: a tablet similar to the actual broccoli sprout extract though without BSE.
normal saline nasal spray: normal saline to replace nasal fluticasone in specific arms of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Nasal Inspiratory Flow (PNIF) Change From Baseline to 3 Weeks of Randomly Assigned Treatment</title>
          <description>peak nasal inspiratory flow (PNIF) measures the peak flow during nasal inspiration with an approved device utilized in other studies. Measurements will be performed with TNSS (above).</description>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".3362" spread=".0026"/>
                    <measurement group_id="O2" value=".1213" spread=".0607"/>
                    <measurement group_id="O3" value=".0636" spread=".0485"/>
                    <measurement group_id="O4" value="-.0538" spread=".0453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interleukin 5 (IL5)</title>
        <description>Interleukin 5 (IL5) is considered a T2 cytokine that increases with exacerbations of atopic disease, including allergic rhinitis. Cytokine measurements are in pg/ml. Values are recorded with log transformation. Note that measurements are on a continuous score. Lower values are consistent with less T2 inflammation which is consistent with diminished or lower atopic/allergic response.</description>
        <time_frame>21 days (from randomization to completion)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BSE + Nasal Fluticasone</title>
            <description>patients received combination of broccoli sprout extract tablet and nasal fluticasone for a total of 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>BSE + Normal Saline Nasal Spray</title>
            <description>Patients received broccoli sprout extract tablets and nasal saline spray for 3 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Pill + Nasal Fluticasone</title>
            <description>Patients received placebo tablet and nasal fluticasone for 3 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Pill + Normal Saline Nasal Spray</title>
            <description>Patients received placebo tablet and normal saline nasal spray for 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin 5 (IL5)</title>
          <description>Interleukin 5 (IL5) is considered a T2 cytokine that increases with exacerbations of atopic disease, including allergic rhinitis. Cytokine measurements are in pg/ml. Values are recorded with log transformation. Note that measurements are on a continuous score. Lower values are consistent with less T2 inflammation which is consistent with diminished or lower atopic/allergic response.</description>
          <units>log(pg/ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.5285" spread=".2236"/>
                    <measurement group_id="O2" value="-.3213" spread=".2005"/>
                    <measurement group_id="O3" value="-.1082" spread=".0083"/>
                    <measurement group_id="O4" value="-.3755" spread="0.1866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interleukin 4 (IL4)</title>
        <description>Interleukin 4 (IL4) is considered a T2 cytokine that increases with exacerbations of atopic disease, including allergic rhinitis. Cytokine measurements are in pg/ml. Values are recorded with log transformation. Note that measurements are on a continuous score. Lower values are consistent with less T2 inflammation which is consistent with diminished or lower atopic/allergic response.</description>
        <time_frame>21 days (from randomization to completion)</time_frame>
        <population>Patient diagnosed with grass induced allergic rhinitis were randomized into 1 of 4 groups.</population>
        <group_list>
          <group group_id="O1">
            <title>BSE + Nasal Fluticasone</title>
            <description>subjects will be randomized into 1 of 4 arms:
BSE + Nasal Fluticasone
BSE + normal saline nasal spray
Placebo Pill + Nasal Fluticasone
Placebo Pill + normal saline nasal spray
Broccoli Sprout Extract: Broccoli Sprout Extract contains the antioxidant Sulforaphane which is the active ingredient being studies.
fluticasone nasal: fluticasone is a nasal steroid that is currently approved for treatment of allergic rhinitis.</description>
          </group>
          <group group_id="O2">
            <title>BSE + Normal Saline Nasal Spray</title>
            <description>subjects will be randomized into 1 of 4 arms:
BSE + Nasal Fluticasone
BSE + normal saline nasal spray
Placebo Pill + Nasal Fluticasone
Placebo Pill + normal saline nasal spray
Broccoli Sprout Extract: Broccoli Sprout Extract contains the antioxidant Sulforaphane which is the active ingredient being studies.
normal saline nasal spray: normal saline to replace nasal fluticasone in specific arms of the study</description>
          </group>
          <group group_id="O3">
            <title>Placebo Pill + Nasal Fluticasone</title>
            <description>subjects will be randomized into 1 of 4 arms:
BSE + Nasal Fluticasone
BSE + normal saline nasal spray
Placebo Pill + Nasal Fluticasone
Placebo Pill + normal saline nasal spray
fluticasone nasal: fluticasone is a nasal steroid that is currently approved for treatment of allergic rhinitis.
broccoli sprout extract placebo: a tablet similar to the actual broccoli sprout extract though without BSE.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Pill + Normal Saline Nasal Spray</title>
            <description>subjects will be randomized into 1 of 4 arms:
BSE + Nasal Fluticasone
BSE + normal saline nasal spray
Placebo Pill + Nasal Fluticasone
Placebo Pill + normal saline nasal spray
broccoli sprout extract placebo: a tablet similar to the actual broccoli sprout extract though without BSE.
normal saline nasal spray: normal saline to replace nasal fluticasone in specific arms of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin 4 (IL4)</title>
          <description>Interleukin 4 (IL4) is considered a T2 cytokine that increases with exacerbations of atopic disease, including allergic rhinitis. Cytokine measurements are in pg/ml. Values are recorded with log transformation. Note that measurements are on a continuous score. Lower values are consistent with less T2 inflammation which is consistent with diminished or lower atopic/allergic response.</description>
          <population>Patient diagnosed with grass induced allergic rhinitis were randomized into 1 of 4 groups.</population>
          <units>log(pg/ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.5655" spread="0.4738"/>
                    <measurement group_id="O2" value="-.1076" spread=".0228"/>
                    <measurement group_id="O3" value="-.3682" spread=".0294"/>
                    <measurement group_id="O4" value="-.3695" spread=".233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interleukin 6 (IL6)</title>
        <description>Interleukin 6 is a cytokine present during inflammatory process. This is recorded in pg/ml. Below is the log transformation of the pg/ml unit. Note that measurements are on a continuous score. Lower values are consistent with less inflammation which could occur with an inflammatory response.</description>
        <time_frame>21 days (from randomization to completion)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BSE + Nasal Fluticasone</title>
            <description>patients received combination of broccoli sprout extract tablet and nasal fluticasone for a total of 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>BSE + Normal Saline Nasal Spray</title>
            <description>Patients received broccoli sprout extract tablets and nasal saline spray for 3 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Pill + Nasal Fluticasone</title>
            <description>Patients received placebo tablet and nasal fluticasone for 3 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Pill + Normal Saline Nasal Spray</title>
            <description>Patients received placebo tablet and normal saline nasal spray for 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin 6 (IL6)</title>
          <description>Interleukin 6 is a cytokine present during inflammatory process. This is recorded in pg/ml. Below is the log transformation of the pg/ml unit. Note that measurements are on a continuous score. Lower values are consistent with less inflammation which could occur with an inflammatory response.</description>
          <units>log(pg/ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0868" spread=".2903"/>
                    <measurement group_id="O2" value="-.0519" spread=".2437"/>
                    <measurement group_id="O3" value="-.2719" spread="1.6894"/>
                    <measurement group_id="O4" value=".3567" spread=".2826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interleukin 8 (IL8)</title>
        <description>Interleukin 8 s a cytokine that will increase with inflammation. Below is the log transformation of the pg/ml unit. Note that measurements are on a continuous score. Lower values are consistent with less inflammation which could occur with an inflammatory response.</description>
        <time_frame>21 days (from randomization to completion)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BSE + Nasal Fluticasone</title>
            <description>patients received combination of broccoli sprout extract tablet and nasal fluticasone for a total of 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>BSE + Normal Saline Nasal Spray</title>
            <description>Patients received broccoli sprout extract tablets and nasal saline spray for 3 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Pill + Nasal Fluticasone</title>
            <description>Patients received placebo tablet and nasal fluticasone for 3 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Pill + Normal Saline Nasal Spray</title>
            <description>Patients received placebo tablet and normal saline nasal spray for 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin 8 (IL8)</title>
          <description>Interleukin 8 s a cytokine that will increase with inflammation. Below is the log transformation of the pg/ml unit. Note that measurements are on a continuous score. Lower values are consistent with less inflammation which could occur with an inflammatory response.</description>
          <units>pg/ml log transformation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.7626" spread=".0168"/>
                    <measurement group_id="O2" value="-.047" spread=".0033"/>
                    <measurement group_id="O3" value="-.1013" spread=".2629"/>
                    <measurement group_id="O4" value=".0472" spread=".1748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interleukin 13 (IL13)</title>
        <description>Interleukin 13 (IL13) is considered a T2 cytokine that increases with exacerbations of atopic disease, including allergic rhinitis. Cytokine measurements are in pg/ml. Values are recorded with log transformation. Note that measurements are on a continuous score. Lower values are consistent with less T2 inflammation which is consistent with diminished or lower atopic/allergic response.</description>
        <time_frame>21 days (from randomization to completion)</time_frame>
        <population>Patient diagnosed with grass induced allergic rhinitis were randomized into 1 of 4 groups.</population>
        <group_list>
          <group group_id="O1">
            <title>BSE + Nasal Fluticasone</title>
            <description>patients received combination of broccoli sprout extract tablet and nasal fluticasone for a total of 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>BSE + Normal Saline Nasal Spray</title>
            <description>Patients received broccoli sprout extract tablets and nasal saline spray for 3 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Pill + Nasal Fluticasone</title>
            <description>Patients received placebo tablet and nasal fluticasone for 3 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Pill + Normal Saline Nasal Spray</title>
            <description>Patients received placebo tablet and normal saline nasal spray for 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin 13 (IL13)</title>
          <description>Interleukin 13 (IL13) is considered a T2 cytokine that increases with exacerbations of atopic disease, including allergic rhinitis. Cytokine measurements are in pg/ml. Values are recorded with log transformation. Note that measurements are on a continuous score. Lower values are consistent with less T2 inflammation which is consistent with diminished or lower atopic/allergic response.</description>
          <population>Patient diagnosed with grass induced allergic rhinitis were randomized into 1 of 4 groups.</population>
          <units>log(pg/ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0822" spread=".2568"/>
                    <measurement group_id="O2" value="-.2985" spread=".0466"/>
                    <measurement group_id="O3" value=".1577" spread=".1042"/>
                    <measurement group_id="O4" value="-.0459" spread=".3745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interleukin 1 Beta (IL1b)</title>
        <description>IL1b is a cytokine that will increase with inflammation. Below is the log transformation of the pg/ml unit. Note that measurements are on a continuous score. Lower values are consistent with less inflammation which could occur with an inflammatory response.</description>
        <time_frame>21 days (from randomization to completion)</time_frame>
        <population>Patient diagnosed with grass induced allergic rhinitis were randomized into 1 of 4 groups</population>
        <group_list>
          <group group_id="O1">
            <title>BSE + Nasal Fluticasone</title>
            <description>patients received combination of broccoli sprout extract tablet and nasal fluticasone for a total of 3 weeks</description>
          </group>
          <group group_id="O2">
            <title>BSE + Normal Saline Nasal Spray</title>
            <description>Patients received broccoli sprout extract tablets and nasal saline spray for 3 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Pill + Nasal Fluticasone</title>
            <description>Patients received placebo tablet and nasal fluticasone for 3 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Pill + Normal Saline Nasal Spray</title>
            <description>Patients received placebo tablet and normal saline nasal spray for 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin 1 Beta (IL1b)</title>
          <description>IL1b is a cytokine that will increase with inflammation. Below is the log transformation of the pg/ml unit. Note that measurements are on a continuous score. Lower values are consistent with less inflammation which could occur with an inflammatory response.</description>
          <population>Patient diagnosed with grass induced allergic rhinitis were randomized into 1 of 4 groups</population>
          <units>pg/ml with log transformation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.4058" spread=".2563"/>
                    <measurement group_id="O2" value=".0183" spread=".037"/>
                    <measurement group_id="O3" value="-.2382" spread=".3013"/>
                    <measurement group_id="O4" value=".0713" spread=".1139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected throughout the study. 1 year 6 months total.</time_frame>
      <desc>Intermittent sneezing, expected adverse event. Flatulence, expected adverse event General: &quot;cold like symptoms&quot;, unrelated, expected given time of year
Nasal irritation after nasal saline spray, unrelated, unexpected :
GI: hemorrhoids: unexpected, unrelated Chest pain: secondary to rib injury: unrelated, unexpected GI: bloating: expected</desc>
      <group_list>
        <group group_id="E1">
          <title>BSE + Nasal Fluticasone</title>
          <description>subjects will be randomized into 1 of 4 arms:
BSE + Nasal Fluticasone
BSE + normal saline nasal spray
Placebo Pill + Nasal Fluticasone
Placebo Pill + normal saline nasal spray
Broccoli Sprout Extract: Broccoli Sprout Extract contains the antioxidant Sulforaphane which is the active ingredient being studies.
no adverse events reported fluticasone nasal: fluticasone is a nasal steroid that is currently approved for treatment of allergic rhinitis.</description>
        </group>
        <group group_id="E2">
          <title>BSE + Normal Saline Nasal Spray</title>
          <description>subjects will be randomized into 1 of 4 arms:
BSE + Nasal Fluticasone
BSE + normal saline nasal spray
Placebo Pill + Nasal Fluticasone
Placebo Pill + normal saline nasal spray
Broccoli Sprout Extract: Broccoli Sprout Extract contains the antioxidant Sulforaphane which is the active ingredient being studies.
normal saline nasal spray: normal saline to replace nasal fluticasone in specific arms of the study</description>
        </group>
        <group group_id="E3">
          <title>Placebo Pill + Nasal Fluticasone</title>
          <description>subjects will be randomized into 1 of 4 arms:
BSE + Nasal Fluticasone
BSE + normal saline nasal spray
Placebo Pill + Nasal Fluticasone
Placebo Pill + normal saline nasal spray
fluticasone nasal: fluticasone is a nasal steroid that is currently approved for treatment of allergic rhinitis.
broccoli sprout extract placebo: a tablet similar to the actual broccoli sprout extract though without BSE.</description>
        </group>
        <group group_id="E4">
          <title>Placebo Pill + Normal Saline Nasal Spray</title>
          <description>subjects will be randomized into 1 of 4 arms:
BSE + Nasal Fluticasone
BSE + normal saline nasal spray
Placebo Pill + Nasal Fluticasone
Placebo Pill + normal saline nasal spray
broccoli sprout extract placebo: a tablet similar to the actual broccoli sprout extract though without BSE.
normal saline nasal spray: normal saline to replace nasal fluticasone in specific arms of the study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>sneezing</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gi complaints</sub_title>
                <description>Flatulence</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>gi complaint</sub_title>
                <description>hemorrhoids</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>abdominal bloating</sub_title>
                <description>abdominal bloating</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <description>diarrhea</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <description>nausea</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>nasal symptom</sub_title>
                <description>sneezing</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>viral urti</sub_title>
                <description>viral upper respiratory track infection (nasal congestion, sneezing and rhinorrhea)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>nasal irritation</sub_title>
                <description>nasal irritation</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>costochondritis</sub_title>
                <description>patient went to ER during study for check pain that was reproducible and diagnosed with costochondritis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>1. Difficult recruiting enough patients</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Joseph Yusin Chief division Allergy Immunology</name_or_title>
      <organization>VA Greater Los Angeles Healthcare System</organization>
      <phone>3104783711 ext 40230</phone>
      <email>joseph.yusin2@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

